Biogen’s Spinraza Stays Ahead Of Novartis And Roche Challengers In SMA – For Now
Evrysdi Growing Fast
Biogen is hoping to stem the decline in its blockbuster’s revenues but Novartis’ Zolgensma and Roche’s Evrysdi look hard to stop.
Biogen is hoping to stem the decline in its blockbuster’s revenues but Novartis’ Zolgensma and Roche’s Evrysdi look hard to stop.